



Second-quarter 2026 results

Worldwide sales

\$12.6B

↑4.8%¹

On a comparable basis*

Adjusted diluted EPS

\$1.31²

Exceeded the midpoint of our guidance and the consensus estimate

Full-year 2026 guidance³

Reaffirmed comparable sales growth guidance range of

6.5% to 7.5%

Raised adjusted diluted EPS guidance range to

\$5.45 to \$5.60

Key business units | Second-quarter sales



\$5.9B

Medical Devices



\$3.1B

Diagnostics



\$2.1B

Nutrition



\$1.5B

Established Pharmaceuticals

Second-quarter business highlights



Leadership in noninvasive colorectal cancer (CRC) screening

With 50 million Americans not up to date on CRC screening, the American Cancer Society reaffirmed Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults age 45 and older who are at average risk for CRC



Breakthrough biowearables for people with diabetes

Secured CE Mark for Libre® Duo systems, the world's first dual glucose-ketone sensing technology, which supports daily diabetes management and helps detect rising ketone levels that can lead to a diabetic ketoacidosis emergency



Next-generation cardiovascular technologies

Completed enrollment in our TECTONIC U.S. pivotal trial evaluating our investigational Coronary Intravascular Lithotripsy System and shared late-breaking data at the Heart Rhythm Society conference demonstrating strong clinical outcomes across our pulsed field ablation and conduction system pacing portfolios

*Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments received by the Structural Heart business under a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

1. On a GAAP basis, second-quarter Abbott sales increased 13.0%. 2. Second-quarter 2026 GAAP diluted EPS was \$0.53. 3. Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

Forward-looking statements

Some statements in this material may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.